The genetics of hepatitis C virus underlie its ability to escape humoral immunity
dc.contributor.author | Kolls, Jay K. | |
dc.contributor.author | Szabo, Gyongyi | |
dc.date | 2022-08-11T08:08:32.000 | |
dc.date.accessioned | 2022-08-23T15:58:08Z | |
dc.date.available | 2022-08-23T15:58:08Z | |
dc.date.issued | 2015-01-01 | |
dc.date.submitted | 2015-05-29 | |
dc.identifier.citation | J Clin Invest. 2015 Jan;125(1):97-8. doi: 10.1172/JCI79424. Epub 2014 Dec 15. <a href="http://dx.doi.org/10.1172/JCI79424">Link to article on publisher's site</a> | |
dc.identifier.issn | 0021-9738 (Linking) | |
dc.identifier.doi | 10.1172/JCI79424 | |
dc.identifier.pmid | 25500881 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/30365 | |
dc.description.abstract | Hepatitis C virus (HCV) is a leading cause of chronic liver disease, and efforts to develop therapeutic vaccine strategies have been limited by immune escape due to HCV variants that are resistant to current vaccines or HCV variants that rapidly acquire new resistance-conferring mutations. Recently, the crystal structure of the viral envelope protein E2 region was resolved as well as how E2 docks to the host CD81 protein; therefore, antibodies that block this interaction should prevent viral entry into host cells. In this issue of the JCI, Bailey and colleagues show that immune escape of HCV can occur by naturally occurring polymorphisms in E2 that are distinct from those at mapped sites of antibody binding. These data reveal alternative mechanisms of resistance that need to be considered in both natural viral escape as well as in rationale vaccine design against HCV. | |
dc.language.iso | en_US | |
dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=25500881&dopt=Abstract">Link to Article in PubMed</a> | |
dc.rights | Publisher PDF posted as allowed by the publisher's author rights policy at http://static.the-jci.org/content_assets/admin/forms/jcicopyright.pdf. | |
dc.subject | Antibodies, Neutralizing | |
dc.subject | Hepacivirus | |
dc.subject | Humans | |
dc.subject | *Neutralization Tests | |
dc.subject | *Polymorphism, Genetic | |
dc.subject | Digestive System Diseases | |
dc.subject | Gastroenterology | |
dc.subject | Genetics | |
dc.subject | Immunity | |
dc.subject | Immunoprophylaxis and Therapy | |
dc.title | The genetics of hepatitis C virus underlie its ability to escape humoral immunity | |
dc.type | Journal Article | |
dc.source.journaltitle | The Journal of clinical investigation | |
dc.source.volume | 125 | |
dc.source.issue | 1 | |
dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1635&context=faculty_pubs&unstamped=1 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/faculty_pubs/636 | |
dc.identifier.contextkey | 7158515 | |
refterms.dateFOA | 2022-08-23T15:58:09Z | |
html.description.abstract | <p>Hepatitis C virus (HCV) is a leading cause of chronic liver disease, and efforts to develop therapeutic vaccine strategies have been limited by immune escape due to HCV variants that are resistant to current vaccines or HCV variants that rapidly acquire new resistance-conferring mutations. Recently, the crystal structure of the viral envelope protein E2 region was resolved as well as how E2 docks to the host CD81 protein; therefore, antibodies that block this interaction should prevent viral entry into host cells. In this issue of the JCI, Bailey and colleagues show that immune escape of HCV can occur by naturally occurring polymorphisms in E2 that are distinct from those at mapped sites of antibody binding. These data reveal alternative mechanisms of resistance that need to be considered in both natural viral escape as well as in rationale vaccine design against HCV.</p> | |
dc.identifier.submissionpath | faculty_pubs/636 | |
dc.contributor.department | Department of Medicine, Division of Gastroenterology | |
dc.source.pages | 97-8 |